Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Nov;27(6):723-734.
doi: 10.1007/s40272-025-00719-0. Epub 2025 Sep 22.

Current Treatment Modalities for Urea Cycle Disorders

Affiliations
Review

Current Treatment Modalities for Urea Cycle Disorders

Nicholas Ah Mew et al. Paediatr Drugs. 2025 Nov.

Abstract

The urea cycle, a metabolic pathway comprising six enzymes and two transporters, is necessary for mammalian nitrogen detoxification. A deficiency of any of these components disrupts this process, leading to the accumulation of nitrogen in the form of ammonia, which is especially toxic to the brain. For decades, treatment of urea cycle disorders has consisted of nitrogen scavengers, dietary protein restriction, arginine or citrulline supplementation, calorie support, and liver transplant. In 2011, carglumic acid became available as a substitute for N-acetylglutamate for N-acetylglutamate synthase deficiency. The past 10 years, however, have seen the development of enzyme therapy for arginase deficiency and gene therapy for ornithine transcarbamylase deficiency. This article reviews the current status and availability of treatment options for urea cycle disorders.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of Interest/Competing Interests: Uta Lichter-Konecki has no conflicts of interest that are relevant to the content of this article. Nicholas Ah Mew is a medical advisor to the National Urea Cycle Disorders Foundation and Citrin Foundation, serves on the Data Safety Monitoring Board of clinical trials conducted by iECURE and Arcturus Therapeutics, and is a consultant to Ultragenyx Pharmaceutical and Moderna. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Availability of Data and Material: Not applicable. Code Availability: Not applicable. Authors’ Contributions: ULK and NA contributed equally to both drafting and editing the manuscript. ULK and NA read and approved the final version of the manuscript, and agree to be accountable for the work.

References

    1. Lichter-Konecki U, Sanz JH, McCarter R, Urea Cycle Disorders Consortium. Relationship between longitudinal changes in neuropsychological outcome and disease biomarkers in urea cycle disorders. Pediatr Res. 2023;94(6):2005–15. - PubMed
    1. Lichter-Konecki U, Mangin JM, Gordish-Dressman H, Hoffman EP, Gallo V. Gene expression profiling of astrocytes from hyperammonemic mice reveals altered pathways for water and potassium homeostasis in vivo. Glia. 2008;56(4):365–77. - PubMed - PMC
    1. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med. 2007;356(22):2282–92. - PubMed
    1. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001;138(1 Suppl):S46–55. - PubMed
    1. Ah Mew N, McCarter R, Daikhin Y, Lichter-Konecki U, Nissim I, Yudkoff M, et al. Augmenting ureagenesis in patients with partial carbamyl phosphate synthetase 1 deficiency with N-carbamyl-L-glutamate. J Pediatr. 2014;165(2):401-3.e3. - PubMed - PMC

LinkOut - more resources